Shire (LON:SHP)‘s stock had its “equal weight” rating reissued by stock analysts at Barclays in a research note issued to investors on Friday.
SHP has been the topic of several other reports. Deutsche Bank restated a “buy” rating on shares of Shire in a report on Friday, October 12th. Shore Capital lowered shares of Shire to a “hold” rating in a report on Thursday, June 21st. Liberum Capital restated a “hold” rating on shares of Shire in a report on Tuesday, July 10th. Berenberg Bank lowered shares of Shire to a “hold” rating and boosted their price objective for the company from GBX 4,500 ($58.80) to GBX 5,000 ($65.33) in a report on Thursday, September 6th. Finally, UBS Group reiterated a “neutral” rating and set a GBX 4,500 ($58.80) price target on shares of Shire in a research note on Wednesday, August 1st. Eight analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. Shire presently has an average rating of “Buy” and an average target price of GBX 4,693.14 ($61.32).
Shares of SHP opened at GBX 4,513 ($58.97) on Friday. Shire has a 12-month low of GBX 2,940.50 ($38.42) and a 12-month high of GBX 5,021 ($65.61).
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Read More: Why do company’s buyback their stock?
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.